E
Sell
4/1/2025Downgrade
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E+ from D- on 4/1/2025 due to a decline in the total return index, volatility index and solvency index. The quick ratio declined from 12.65 to 10.43.
D
Sell
3/14/2025Upgraded
Acrivon Therapeutics, Inc. (ACRV) was upgraded to D- from E+ on 3/14/2025 due to an increase in the volatility index.
E
Sell
2/27/2025Downgrade
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E+ from D- on 2/27/2025 due to a decline in the volatility index and total return index.
D
Sell
2/12/2025Upgraded
Acrivon Therapeutics, Inc. (ACRV) was upgraded to D- from E+ on 2/12/2025 due to an increase in the volatility index and total return index.
E
Sell
1/27/2025Downgrade
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E+ from D- on 1/27/2025 due to a decline in the growth index and volatility index. Operating cash flow declined 24.6% from -$13.9M to -$17.32M, EBIT declined 17.27% from -$21.44M to -$25.14M, and earnings per share declined from -$0.5203 to -$0.5889.
D
Sell
4/25/2024Upgraded
Acrivon Therapeutics, Inc. (ACRV) was upgraded to D- from E+ on 4/25/2024 due to an increase in the total return index and volatility index.
E
Sell
10/23/2023Downgrade
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E+ from D- on 10/23/2023 due to a major decline in the efficiency index, growth index and total return index. Net income declined 9.08% from -$12.76M to -$13.91M, earnings per share declined from -$0.5819 to -$0.6333, and EBIT declined 7.83% from -$14.39M to -$15.52M.
D
Sell
8/1/2023Upgraded
Acrivon Therapeutics, Inc. (ACRV) was upgraded to D- from E on 08/01/2023.
E
Sell
5/31/2023Downgrade
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E from E+ on 5/31/2023 due to a decline in the volatility index, solvency index and total return index.
E
Sell
5/1/2023Upgraded
Acrivon Therapeutics, Inc. (ACRV) was upgraded to E+ from E on 5/1/2023 due to a significant increase in the solvency index and total return index. The quick ratio increased from 12.02 to 19.61.
E
Sell
2/10/2023None
Acrivon Therapeutics, Inc. (ACRV) was downgraded to E from U on 02/10/2023.
